Weave Communications, Inc. (NYSE:WEAV)的主要股东Crosslink Capital Inc.最近出售了89,555股该公司普通股。这笔交易发生在2024年11月1日，每股交易价格为12.98美元，总销售额约为116万美元。 此次出售后，Crosslink Capital持有约8,116,688股Weave Communications股票。这笔交易是Cross ...

2024年10月，山东安华生物医药股份有限公司收到美国食品药品监督管理局（FDA）cGMP检查报告（EIR），公司正式通过FDA cGMP审查。

Last, our partnership with CrossLink continues to progress and we are now beginning to see the positive impact that this ...

Earlier, I spoke about VAN. And the Nopain Act, both of which will have an impact in 2025. Right now. We are seeing early results that the Crosslink partnership is beginning to drive growth. Our team ...

Heron Therapeutics在2024年10月30日的第三季度财报电话会议上更新了2024年第四季度的财务指引,预计净收入将在3700万美元至4300万美元之间,反映了本季度的早期成功。公司宣布已获得FDA批准其Vial Access Needle (VAN),预计将改善其药物ZYNRELEF的给药方式。

Heron Therapeutics Inc (HRTX) reports a significant increase in gross profit margin and outlines strategic plans to overcome revenue hurdles in a competitive market.

Pacira BioSciences(PCRX)发布Q3财报，2024财年前三财季累计收入5.14亿美元，去年同期累计收入为4.94亿美元，同比增长4.05%。 2024财年前三财季累计净亏损1.16亿美元，去年同期累计净利润为1708.50万美元。 本财年累计基本每股收益为-2.5美元，去年同期为0.37美元。 公司所属行业为制药。 营业收入-1.39亿 2910.50万 1379.90万 33 ...

Count defense tech bulls among the investor groups buoyed by last week’s election of Donald Trump as president. Some ...

Based on technology from Johns Hopkins University, Glyscend’s lead candidate, GLY-200, is designed to crosslink native GI tract mucin in a pH-dependent manner, enhancing the natural mucus ...

This valuable study reveals extensive binding of eukaryotic translation initiation factor 3 (eIF3) to the 3' untranslated regions (UTRs) of efficiently translated mRNAs in human pluripotent stem ...